TOP > 外国特許検索 > ANTIBODY RECOGNIZING FOLATE RECEPTORS α AND β

ANTIBODY RECOGNIZING FOLATE RECEPTORS α AND β

外国特許コード F150008058
整理番号 S2013-0319-C0
掲載日 2015年1月8日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP085026
国際公開番号 WO 2014104270
国際出願日 平成25年12月19日(2013.12.19)
国際公開日 平成26年7月3日(2014.7.3)
優先権データ
  • 特願2012-281525 (2012.12.25) JP
発明の名称 (英語) ANTIBODY RECOGNIZING FOLATE RECEPTORS α AND β
発明の概要(英語) The purpose of the present invention is to provide an antibody that immunologically and specifically binds to folate receptor α and folate receptor β. Specifically disclosed is an antibody or a fragment thereof, wherein the amino acid sequences of the CDRH1, CDRH2 and CDRH3 of a heavy chain variable region (VH) are respectively the amino acid sequences of SEQ ID NOS:2, 4 and 6, and the amino acid sequences of the CDRL1, CDRL2 and CDRL3 of a light chain variable region (VL) are respectively the amino acid sequences of SEQ ID NOS:10, 12 and 14.
従来技術、競合技術の概要(英語) BACKGROUND ART
(FR) folic acid receptor and oxidized form of folic acid receptor, a human cell is FR α, and the presence FR β FR γ isoforms are known (non-patent document 1). Is FR α, and expressed on the surface of epithelial cells, a variety of cancer cells to increase expression. Recently, anti-FR α antibody is used in the ovarian cancer patient clinical trials phase II in the United States, its effect could be confirmed (non-patent document 2). In addition, the patent document 1, anti-ovarian cancer antibody FR α treatment composition is disclosed. On the other hand, reduced expression of the healthy tissue FR β, synovial rheumatoid arthritis, osteoarthritis synovial, pulmonary fibrosis of lung tissue such as expressed on the surface of the inflamed tissue is seen in activated macrophages (non-patent document 3-5). Further, inventors of the present invention, anti-human FR β producing antibodies, cancer-associated macrophages present in the tissue in a variety of cancers FR β expression in many of the macrophage, and pancreatic cancer cancer FR β expression in macrophages increases the number of poor prognosis for life (non-patent document 6) shown. In addition, the present inventors, in malignant glioma xenograft model, using anti-FR β FR β antibody immunotoxins by removing macrophages, suppressed the growth of malignant glioma showed (non-patent document 7). Further, the patent document 2-4, FR-β antibodies and the antibody and the toxin can be connected to the FR-β antibody immunotoxins, as well as antibodies and immunotoxins containing the disclosed therapeutic agents. As described above, up to now such as anti-anti-antibody or antibody immunotoxins FR α FR β alone due to the use of anti-FR β antibody binding on the proliferation of cancer is known. However, anti-FR β that binds to anti-FR α that binds to the compound of the compound of the cancer by combination therapy using an anti-proliferative effect has not been reported. In addition, the FR α FR β and, at the amino acid level having a homology of about 70% is, so far and antibodies that recognize both FR α FR β has not been reported.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • MATSUYAMA, Takami
  • NAGAI, Taku
  • HASUI, Kazuhisa
  • TAKAO, Sonshin
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close